ATA Differentiated Thyroid Cancer Derivative

Differentiated Thyroid Cancer Guidelines

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/706038

Contents of this Issue

Navigation

Page 9 of 11

Differentiated Thyroid Cancer Management 10 Table 4. Response to Therapy Re-Classification Excellent response An excellent response to therapy should lead to a decrease in the intensity and frequency of follow up and the degree of TSH suppression. Note: This change in management will be most apparent in ATA intermediate and high risk patients. Biochemical incomplete response If associated with stable or declining serum Tg values, a biochemical incomplete response should lead to continued observation with ongoing TSH suppression in most patients. Rising Tg or Tg antibody values should prompt additional imaging and potentially additional therapies. Structural incomplete response A structural incomplete response may lead to additional treatments or ongoing observation depending on multiple clinico-pathologic factors including the size, location, rate of growth, RAI avidity, 18 FDG avidity, and specific patholog y of the structural lesions. Indeterminate response An indeterminate response should lead to continued observation with appropriate serial imaging of the non- specific lesions and serum Tg monitoring. Non-specific findings that become suspicious over time or rising Tg or Tg antibodies levels can be further evaluated with additional imaging or biopsy. Guideline Grading System Strength of Recommendation Quality of Evidence SR Strong Recommendation H High-quality evidence WR Weak Recommendation M Moderate-quality evidence NR No Recommendation L Low-quality evidence I Insufficient evidence

Articles in this issue

view archives of ATA Differentiated Thyroid Cancer Derivative - Differentiated Thyroid Cancer Guidelines